Tazobactum%2520piperacillin

#Piperacillin/Tazobactam ## Overview Piperacillin/tazobactam is a beta-lactam/beta-lactamase inhibitor combination. Piperacillin is an antipseudomonal penicillin; tazobactam irreversibly inhibits many class A beta-lactamases (except some ESBLs and carbapenemases). It provides broad gram-negative, gram-positive, and anaerobic coverage. ## Primary Indications - Hospital-acquired pneumonia (including ventilator-associated) - Complicated intra-abdominal infections - Complicated urinary tract infections (including pyelonephritis) - Febrile neutropenia (often with an aminoglycoside) - Skin and soft tissue infections (especially diabetic foot infections) ## Adult Dosing All doses are expressed as grams of piperacillin/tazobactam. Dosing is based on the piperacillin component. - **Standard (moderate-severe infection):** 3.375 g IV every 6 hours (or 4.5 g every 8 hours depending on local protocol). - **Pseudomonal or nosocomial pneumonia:** 4.5 g IV every 6 hours. - **Febrile neutropenia:** 4.5 g IV every 6 hours. - **Max dose:** 18 g/day (4.5 g every 6 hours). Extended infusions (e.g., 3.375 g over 4 hours every 8 hours) may be used in critically ill patients—follow local protocol. ## Pediatric Dosing Weight-based dosing uses the piperacillin component (mg/kg). Typical for complicated infections: - **Neonates (≤7 days):** 100 mg/kg/dose every 12 hours. - **Neonates (8–28 days):** 100 mg/kg/dose every 8 hours. - **Infants and children (<40 kg):** 100 mg/kg/dose every 8 hours (max 4.5 g/dose). - **Children ≥40 kg:** Adult dosing. - **Febrile neutropenia:** 80–100 mg/kg/dose every 6 hours (max 4.5 g/dose) per many protocols. Exact pediatric dosing may vary by indication and local guidelines. ## Dose Adjustments **Renal impairment:** Adjust based on creatinine clearance (CrCl). - CrCl 20–40 mL/min: 3.375 g every 8 hours (or 4.5 g every 12 hours). - CrCl <20 mL/min: 3.375 g every 12 hours (or 4.5 g every 12 hours). - Hemodialysis: 3.375 g every 12 hours, give an additional 0.75 g after dialysis. - **No hepatic adjustment** needed. ## Contraindications - Hypersensitivity to piperacillin, tazobactam, any penicillin, or other beta-lactam antibiotics. - Severe immediate allergic reaction (anaphylaxis) history. ## Adverse Effects - **Common:** Diarrhea (including *C. difficile*), nausea, headache, rash, phlebitis. - **Serious:** Severe cutaneous adverse reactions (SJS, TEN), drug-induced immune thrombocytopenia, acute interstitial nephritis, neutropenia (especially with prolonged use >2 weeks), *Clostridioides difficile* infection. - **Elevated liver enzymes** and **bleeding risk** (prolonged PT/INR) are possible. ## Key Drug Interactions - **Warfarin:** Increased INR/bleeding risk; monitor closely. - **Methotrexate:** Reduced methotrexate clearance; avoid if possible. - **Vecuronium/neuromuscular blockers:** May prolong neuromuscular blockade. - **Probenecid:** Decreases piperacillin clearance (probenecid rarely used). - **Aminoglycosides (gentamicin, tobramycin):** Inactivation can occur if mixed in the same IV line or in renal failure; administer separately. ## Monitoring - **Renal function** (serum Cr, BUN, urine output) at baseline and regularly. - **CBC with differential** weekly for prolonged courses (risk of neutropenia/thrombocytopenia). - **Liver enzymes** if symptoms occur. - **Coagulation panel** (PT/INR) for patients on warfarin or those with bleeding risk. - **Signs of hypersensitivity** during and after infusion. ## Clinical Pearls - **Time-dependent killing:** Target serum concentration > MIC for at least 50% of dosing interval. Extended infusions improve target attainment against resistant organisms. - **Covers Pseudomonas aeruginosa, anaerobes (including Bacteroides fragilis).** - **Does not cover MRSA, ESBL-producing Enterobacteriaceae reliably, or carbapenemase producers.** - **Sodium content:** ~2.35 mEq Na per gram of piperacillin; consider in fluid/electrolyte restricted patients. - **IV compatibility:** Do NOT mix with aminoglycosides in the same bag or IV line—administer separate lines. --- *Educational disclaimer: This information is for educational purposes and does not replace independent clinical judgment. Dosing and indications may vary by institution and patient factors. Always verify current prescribing information, including local antibiograms and guidelines, before initiating therapy.*